Europe - Euronext Milan - BIT:1GRF - ES0171996087 - Common Stock
The current stock price of 1GRF.MI is 12.235 EUR.
ChartMill assigns a technical rating of 2 / 10 to 1GRF.MI.
ChartMill assigns a fundamental rating of 5 / 10 to 1GRF.MI. Both the profitability and the financial health of 1GRF.MI get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months 1GRF.MI reported a non-GAAP Earnings per Share(EPS) of 0.55. The EPS increased by 160.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.96% | ||
| ROA | 1.88% | ||
| ROE | 7.2% | ||
| Debt/Equity | 1.76 |
20 analysts have analysed 1GRF.MI and the average price target is 17.08 EUR. This implies a price increase of 39.59% is expected in the next year compared to the current price of 12.235.
For the next year, analysts expect an EPS growth of 40.91% and a revenue growth 5.37% for 1GRF.MI
Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
GRIFOLS SA
Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158
Sant Cugat del Valles BARCELONA ES
Employees: 23833
Phone: 34935710000
Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
The current stock price of 1GRF.MI is 12.235 EUR. The price increased by 16.69% in the last trading session.
1GRF.MI does not pay a dividend.
1GRF.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The Revenue of GRIFOLS SA (1GRF.MI) is expected to grow by 5.37% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
GRIFOLS SA (1GRF.MI) currently has 23833 employees.